Medicus Pharma (MDCX) announced the enrollment of the first patient in United Arab Emirates SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin. The study is expected to randomize thirty-six patients in six sites in UAE. In addition to Cleveland Clinic Abu Dhabi, the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center and American Hospital of Dubai. Insights Research Organization and Solutions, a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Completes Share Sales to YA II PN
- Medicus Pharma to Showcase Innovations at Maxim Growth Summit 2025
- Medicus Pharma Ltd. to Showcase Biotech Innovations at Dubai Summit
- Medicus Pharma Ltd’s Promising Prospects: Innovative BCC Treatment and Strong FDA Support Drive Buy Rating
- Medicus Pharma Advances Skinject Development with Positive FDA Feedback